期刊文献+

60例实体肿瘤患者外周血干细胞的动员和采集 被引量:6

Mobilization and Collection of Peripheral Blood Stem Cells from60Cases of Solid Cancer
下载PDF
导出
摘要 目的:对60例实体肿瘤患者造血干细胞的动员和采集效果进行分析。方法:采用常规化疗联合造血因子动员剂方法动员肿瘤患者外周血干细胞,CS-3000plus血细胞分离仪和程控冷冻降温方法采集、冷冻保存干细胞。结果:60例患者平均年龄41岁(24~57),Ⅰ期3.4%,Ⅱ期25.0%,Ⅲ期38.3%,Ⅳ期33.3%;肿瘤负荷情况,CR46.6%,PR31.6%。平均采集次数2.6次,MNC5.6×108/kg,CFU-GM2.4×105/kg,BFU-E1.7×104/kg,CD34+10.1×106/kg,CFU-GM第1次收获率50.0%,第2次36.0%。各病种间除CD34+外均无统计学差异。恶性淋巴瘤组CD34+细胞数高于其他病种。一次动员成功率90.0%。干细胞冷冻复苏后平均MNC回收率77.0%,CFU-GM回收率69.0%,BFU-E回收率72.0%。各病种之间回收率无差异。结论:常规化疗联合造血干细胞因子是实体肿瘤外周血干细胞移植的一种有效动员剂。 Objective:To analyse the effects of mobilization and collection of peripheral blood stem cells from60cases of solid cancer.Methods:Peripheral blood stem cells were mo bi -lized by routine chemotherapy combined with progenitor factors.It was collected and conserved by CS-3000plus and program controlled cryprotection.Results:The mean age of the60patients were41years(24~57).StageⅠtumor accounted for3.4%,stageⅡ25.0%,stageⅢ38.3%and stageⅣ33.3%.The CR and PR the overall patients were46.6%and31.6%respectively.The average collection frequency was2.6times.The volume of MNC,CFU-GM,BFU-E,CD 34 were5.6×10 8 /kg,2.4×10 5 /kg,1.7×10 4 /kg,10.1×10 6 /kg respectively.The rate of first successful collec-tion was50.0%and the second36.0%.All of them except CD 34+ had no statistical difference.The CD 34+ cells were higher in malignant lymphoma group than that in other groups.The suc-cessful rate of single mobilization was90.0%.The mean MNC recovery rate of the recovered frozen stem cells was77.0%,CFU-GM69.0%,BFU-E72.0%.No significant difference of recov-ery rate was observed between each group.Conclusion:Routine chemotherapy combined with hemopoietic stem cell factors is an effective mobilizer for peripheral blood stem cell transplanta-tion of solid tumor.The main cause of mobilization failure is chemotherapy combined with inter-feron,severe bone marrow su pression before mobilization or im proper use of mobilizer.
出处 《中国肿瘤临床》 CAS CSCD 北大核心 2002年第3期167-170,共4页 Chinese Journal of Clinical Oncology
基金 天津市科委科研基金资助(编号:983113511)
关键词 造血干细胞 动员剂 血细胞分离仪 实体瘤 采集 Mobilization of hemopoietic stem cells Blood separator
  • 相关文献

参考文献4

二级参考文献5

共引文献34

同被引文献50

  • 1王良绪,禹涛,赵昕,尉达民,祝扬.外周血干细胞的动员和采集及移植后造血重建研究[J].中华血液学杂志,1996,17(5):254-256. 被引量:34
  • 2Mulders P,Figlin R,Dekernion JB,et al.Renal cell carcinima:recent progress and future directions[J].Cancer Res,1997,57(22):5189.
  • 3Childs R,Chernoff A,Contentin N,et al.Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation[J].N Engl J Med,2000,343(11):750.
  • 4Mapara MY,Sykes M.Tolerance and cancer:mechanisms of tumor evasion and strategies for breaking tolerance[J].J Clin Oncol,2004,22(6):1136.
  • 5Barkholt L,Bregni M,Remberger M,et al.Allogeneic haematopoietic stem cell transplantation for metastatic renal carcinoma in Europe[J].Ann Oncol,2006,17(17):1134.
  • 6Shimizu K,Fields RC,Giedlin M,et al.Systemic administration of interleukin-2 enhances therapeutic efficacy of dendritic cell based tumor vaccines[J].Proc Nat Acad USA,1999,96(5):2268.
  • 7Hudes G,Carducci M,Tomczak P,et al.Temsirolimus,interferon alfa,or both for advanced renal-cell carcinoma[J].N Engl J Med,2007,356(22):2271.
  • 8McDermott DF,Regan M,Clark JI,et al.Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and Interferon in patients with metastatic renal cell carcinoma[J].J Clin Oncol,2005,23(1):133.
  • 9Negrier S,Escudier B,Lasset C,et al.Recombinant human interleukin-2,recombinant interferon alfa-2b,or both in metastatic renal cell carcinoma[J].N Engl J Med,1998,338(18):1272.
  • 10Ng WF,Duggan PJ,Ponchel F,et al.Human CD4+CD25+ cells:A naturally occurring population of regulatory T cells[J].Blood,2001,98(9):2736.

引证文献6

二级引证文献10

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部